Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$4.22 -3.2%	$3.96	$2.24 ▼ $19.69	$195.49M	2.81	757,411 shs	316,866 shs
IPHA Innate Pharma	$1.92 +8.5%	$1.96	$1.29 ▼ $3.51	$176.98M	0.21	187,954 shs	17,431 shs
SRZN Surrozen	$8.48 -0.2%	$8.50	$5.90 ▼ $18.17	$72.61M	0.59	22,149 shs	3,347 shs
TNGX Tango Therapeutics	$6.77 -1.3%	$4.12	$1.03 ▼ $12.02	$733.83M	1.63	1.62 million shs	1.26 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	0.00%	-1.40%	+3.18%	+37.91%	-76.81%
IPHA Innate Pharma	0.00%	+10.14%	+1.05%	-2.54%	-12.73%
SRZN Surrozen	0.00%	-0.93%	-14.34%	-13.03%	-9.59%
TNGX Tango Therapeutics	0.00%	+14.17%	+41.04%	+424.81%	-30.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.4132 of 5 stars	3.3	3.0	1.8	1.7	0.6
IPHA Innate Pharma	1.8666 of 5 stars	3.8	3.0	0.0	1.7	0.0
SRZN Surrozen	1.8427 of 5 stars	3.5	2.0	0.0	3.3	0.0
TNGX Tango Therapeutics	1.6212 of 5 stars	3.5	1.0	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	600.37% Upside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	472.92% Upside
SRZN Surrozen	3.00	Buy	$38.50	354.01% Upside
TNGX Tango Therapeutics	3.00	Buy	$10.50	55.10% Upside

Current Analyst Ratings Breakdown

Latest SRZN, FDMT, IPHA, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$23K	8,499.63	N/A	N/A	$11.05 per share	0.38
IPHA Innate Pharma	$12.62M	14.02	N/A	N/A	$0.11 per share	17.45
SRZN Surrozen	$10.65M	6.82	N/A	N/A	($6.55) per share	-1.29
TNGX Tango Therapeutics	$42.07M	17.44	N/A	N/A	$1.86 per share	3.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
SRZN Surrozen	-$63.56M	-$24.96	N/A	N/A	N/A	N/A	-842.90%	-71.32%	8/11/2025 (Estimated)
TNGX Tango Therapeutics	-$130.30M	-$1.22	N/A	N/A	N/A	-322.67%	-62.75%	-39.94%	8/6/2025 (Estimated)

Latest SRZN, FDMT, IPHA, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/11/2025	Q2 2025	SRZN Surrozen	-$1.23	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TNGX Tango Therapeutics	-$0.35	N/A	N/A	N/A	$6.41 million	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
IPHA Innate Pharma	2.52	2.60	2.60
SRZN Surrozen	N/A	10.02	10.02
TNGX Tango Therapeutics	N/A	6.26	6.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
IPHA Innate Pharma	0.16%
SRZN Surrozen	66.57%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	9.60%
IPHA Innate Pharma	31.89%
SRZN Surrozen	45.18%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable
TNGX Tango Therapeutics	90	108.39 million	100.26 million	Optionable

SRZN, FDMT, IPHA, and TNGX Headlines

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.1% - Time to Buy?

July 18 at 9:26 PM | marketbeat.com

TNGX - Tango Therapeutics Inc News - Morningstar

July 16, 2025 | morningstar.comM

Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?

July 14, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 4.6% - Time to Sell?

July 11, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - What's Next?

July 9, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for TNGX Earnings

July 2, 2025 | marketbeat.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts

June 28, 2025 | marketbeat.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 6.5% - Should You Buy?

June 27, 2025 | marketbeat.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

June 27, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 8.3% - Should You Sell?

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - Nasdaq

June 25, 2025 | nasdaq.com

Exchange Traded Concepts LLC Purchases 47,901 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)

June 25, 2025 | marketbeat.com

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

June 23, 2025 | zacks.com

Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials

June 16, 2025 | investing.com

Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical

June 6, 2025 | seekingalpha.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | finance.yahoo.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | globenewswire.com

Tango Therapeutics starts trial for brain cancer drug

May 23, 2025 | uk.investing.com

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN, FDMT, IPHA, and TNGX Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$4.22 -0.14 (-3.21%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.22 0.00 (-0.12%)

As of 07/18/2025 06:16 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Innate Pharma NASDAQ:IPHA

$1.94 +0.16 (+9.30%)

As of 07/18/2025 03:57 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Surrozen NASDAQ:SRZN

$8.48 -0.02 (-0.24%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.44 -0.04 (-0.47%)

As of 07/18/2025 04:04 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Tango Therapeutics NASDAQ:TNGX

$6.77 -0.09 (-1.31%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$6.68 -0.09 (-1.26%)

As of 07/18/2025 07:36 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time